Cited by 43Liver Disease Diagnosis and TreatmentBariatric Surgery and OutcomesMinimally Invasive Surgical Techniques

Endoscopic sleeve gastroplasty — minimally invasive treatment for non-alcoholic fatty liver disease and obesity

Jagtap, Nitin, Kalapala, Rakesh, Katakwar, Abhishek, Sharma, Mithun, Aslam, Mohsin, Gupta, Rajesh, Rao, P Nagaraja, Goud, Rajesh +4 more·2021·Indian Journal of Gastroenterology

Abstract

Introduction Adequate weight loss can lead to reduction in steatosis, inflammation, and fibrosis in patients with obesity and non-alcoholic fatty liver disease (NAFLD). We evaluated the role of endoscopic sleeve gastroplasty (ESG) in patients with obesity and NAFLD. Methods In this single-center prospective study, consecutive adult patients with NAFLD who underwent ESG between November 2018 and May 2019 were included. The primary outcome was the impact of ESG on hepatic parameters: change in alanine aminotransferase (ALT), hepatic steatosis index (HSI), NAFLD fibrosis score (NFS), fibrosis-4 index (FIB-4), and aspartate aminotransferase (AST)-to-platelet ratio index (APRI) from baseline to 6 and 12 months. Secondary outcomes included change in glycated hemoglobin (HbA1c), percentage weight loss, and safety. Analysis of variance with repeated measures was used for statistical analysis. Results A total of 26 patients (mean age [SD] 41.5 [9.58] years; 16 females) with mean (SD) weight of 99.43 (21.89) kg at baseline were included. There was significant improvement in ALT (mean ± SD) from baseline of 59.54 ± 17.02 IU/L to 49.50 ± 11.72 IU/L and 48.42 ± 13.22 IU/L at 6 and 12 months (p = 0.001). Mean (SD) NFS was significantly improved from 0.228 (1.00) at baseline to -0.202 (1.16) and -0.552 (1.08) at 6 and 12 months (p 0.001). Mean (SD) HSI, FIB-4, and APRI scores significantly reduced from baseline to 6 and 12 months (p = 0.001). There was 18.07% total body weight loss at 12 months, with significant improvement in HbA1c. There were no major adverse events. Conclusion ESG is a safe and effective treatment option for patients with NAFLD and obesity causing significant weight loss. Rigorous randomized trials are required to incorporate ESG in NAFLD treatment algorithm.

Integrity signals

Registry

Crossref · 10.1007/s12664-021-01202-7

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Jagtap, N., Kalapala, R., Katakwar, A., Sharma, M., Aslam, M., Gupta, R., Rao, P. N., Goud, R., Tandan, M., Kanakagiri, H., Darishetty, S., & Reddy, D. N.
Affiliations
Asian Institute of Gastroenterology (IN)
Corresponding author
Jagtap, Nitin
Venue
Indian Journal of Gastroenterology
Published
2021-12
Volume
40
Issue
6
Pages
572-579
ISSN
  • 0254-8860 (ISSN-L)
  • 0975-0711
OpenAlex
W4200571306
Cited by
43
References
37
Citations by year
2026: 7 · 2025: 15 · 2024: 7 · 2023: 10 · 2022: 3 · 2021: 1
FWCI
3.78
Type
journal article
Language
en
Open access
closed
Locations
  • Indian Journal of Gastroenterology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
  • Health Sciences › Medicine › Surgery › Minimally Invasive Surgical Techniques
Keywords
endoscopic sleeve gastroplasty, non-alcoholic fatty liver disease, obesity, weight loss, hepatic steatosis, liver fibrosis, alanine aminotransferase, NAFLD fibrosis score, FIB-4, APRI, HbA1c, minimally invasive treatment, inflammation reduction
MeSH terms
Adult, Female, Fibrosis, Glycated Hemoglobin, Humans, Male, Middle Aged, Obesity, Prospective Studies, Gastroplasty, Weight Loss, Treatment Outcome, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review